EPISODE · Apr 1, 2025 · 36 MIN
Cardiovascular Impact of Diabetes Meds
from Medication Talk · host TRC Healthcare
Listen in as our expert panel discusses which diabetes meds have cardiovascular (CV) benefits. We’ll review the evidence and discuss the pros and cons of SGLT2 inhibitors (dapagliflozin, empagliflozin, etc) and GLP-1 agonists (dulaglutide, semaglutide, etc) in patients with or at risk for CV disease.Special Guests:Lauren G. Pamulapati, PharmD, BCACPAssociate Professor, Ambulatory CareVirginia Commonwealth University School of PharmacyClinical Pharmacist, Hayes Willis Health Center/VCU HealthChristie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCPProfessor, Pharmacy PracticeDirector, PGY2 Ambulatory Care Residency ProgramMidwestern University College of Pharmacy, Downers Grove CampusClinical Pharmacist, Northwestern MedicineTRC Editorial Advisory Board Participant:Stephen Carek, MD, CAQSM, DipABLMClinical Associate Professor of Family MedicinePrisma Health/USC-SOMG Family Medicine Residency ProgramUSC School of Medicine GreenvilleFor the purposes of disclosure, Dr. Schumacher reports a relevant financial relationship [CGM for diabetes management] with Abbott (speakers bureau).The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.This podcast is an excerpt from one of TRC’s monthly live CE webinars, the full webinar originally aired in February 2025.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist’s Letter, Pharmacy Technician’s Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights: Chart: Diabetes Medications: Cardiovascular and Kidney ImpactChart: Drugs for Type 2 Diabetes Algorithm: Stepwise Treatment of Type 2 DiabetesChart: Comparison of GLP-1 AgonistsToolbox: Improving Heart Failure CareSend us Fan MailEmail us: [email protected] content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.Learn more about our product offerings at trchealthcare.com.
Embed this episode
What this episode covers
Listen in as our expert panel discusses which diabetes meds have cardiovascular (CV) benefits. We’ll review the evidence and discuss the pros and cons of SGLT2 inhibitors (dapagliflozin, empagliflozin, etc) and GLP-1 agonists (dulaglutide, semaglutide, etc) in patients with or at risk for CV disease. Special Guests: Lauren G. Pamulapati, PharmD, BCACPAssociate Professor, Ambulatory CareVirginia Commonwealth University School of PharmacyClinical Pharmacist, Hayes Willis Health Center/VCU...
NOW PLAYING
Cardiovascular Impact of Diabetes Meds
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.